{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:57:31Z","timestamp":1764687451512},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2001,4]]},"DOI":"10.1016\/s0090-4295(00)00981-x","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T07:02:01Z","timestamp":1034319721000},"page":"224-229","source":"Crossref","is-referenced-by-count":28,"special_numbering":"S1","title":["Prostate cancer chemoprevention: Strategies for designing efficient clinical trials"],"prefix":"10.1016","volume":"57","author":[{"given":"Ronald","family":"Lieberman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0090-4295(00)00981-X_BIB1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0197-2456(94)00XXX-M","article-title":"Design of the prostate cancer prevention trial (PCPT)","volume":"16","author":"Feigal","year":"1995","journal-title":"Control Clin Trials"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB2","unstructured":"Defeating Prostate Cancer: Crucial Direction for Research. Report of the Prostate Cancer Progress Review Group, August 1998; 1998. Bethesda, MD: National Cancer Institute. Available at: http:\/\/www.nci.nih.gov."},{"key":"10.1016\/S0090-4295(00)00981-X_BIB3","doi-asserted-by":"crossref","unstructured":"Greenwald P, and Lieberman R: Chemoprevention trials for prostate cancer, in Chung L, Isaacs W, and Simons J (Eds): Prostate Cancer in the 21st Century. Totowa, NJ, Humana Press Inc., 2001, pp 499\u2013518.","DOI":"10.1385\/1-59259-009-8:499"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X","article-title":"Non-steroidal anti-inflammatory drugs and prostate cancer progression","volume":"77","author":"Norrish","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB5","first-page":"169","article-title":"Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs). Results of a case-control study","volume":"7","author":"Nelson","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB6","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jama.276.24.1957","article-title":"Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized control trial","volume":"276","author":"Clark","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jnci\/90.6.440","article-title":"Prostate cancer and supplementation with alpha-tocopherol and beta-carotene. Incidence and mortality in a controlled trial","volume":"90","author":"Heinonen","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB8","doi-asserted-by":"crossref","unstructured":"Kelloff GJ, Lieberman R, Steele VE, et al: Chemoprevention of prostate cancer: concepts and strategies. Eur Urol; 35:342\u2013350, 1999.","DOI":"10.1159\/000019906"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.pcan.4500274","article-title":"Strategies for chemoprevention of prostate cancer","volume":"2","author":"Kelloff","year":"1999","journal-title":"Prostate Cancer Prostate Dis"},{"issue":"2","key":"10.1016\/S0090-4295(00)00981-X_BIB10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/clinchem\/44.2.420","article-title":"Development of new cancer chemoprevention agents","volume":"44","author":"Lieberman","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0022-5347(17)35487-3","article-title":"The frequency of carcinoma and intraepithelial neoplasia of prostate in young male patients","volume":"150","author":"Sakr","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB12","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/1097-0142(19920315)69:6+<1636::AID-CNCR2820691319>3.0.CO;2-6","article-title":"Computer-generated diagnosis and image analysis","volume":"69","author":"Bartels","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB13","doi-asserted-by":"crossref","unstructured":"Strausberg RL, Dahl CA, and Klausner RD. New opportunities for uncovering the molecular basis of cancer. Nat Genet 15: 415\u2013416, 1997.","DOI":"10.1038\/ng0497supp-415"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB14","doi-asserted-by":"crossref","unstructured":"Kurhanewicz J, Vigneson DB, Hricak A, et al: Three-dimensional H-1, MR spectroscopic of the in situ human prostate with high (0.24\u20130.7-cm3) spatial resolution. Radiology 198: 795\u2013805, 1996.","DOI":"10.1148\/radiology.198.3.8628874"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1097-0045(19990915)41:1<12::AID-PROS3>3.0.CO;2-#","article-title":"Nuclear chromatin texture analysis of non-malignant tissue can detect adjacent prostate adenocarcinoma","volume":"41","author":"Mairinger","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB16","first-page":"397","article-title":"Nuclear chromatin texture in prostate lesions. II. Pin and malignancy associated changes","volume":"20","author":"Bartels","year":"1998","journal-title":"Anal Quant Cyt Histol"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB17","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1126\/science.274.5291.1371","article-title":"Major susceptibil-ity locus for prostate cancer on chromosome 1 suggested by a genome-wide search","volume":"274","author":"Smith","year":"1996","journal-title":"Science"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB18","first-page":"191","article-title":"Target populations and strategies, for chemoprevention trials of prostate cancer","volume":"19","author":"Bostwick","year":"1994","journal-title":"J Cell Biochem Suppl"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB20","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0022-5347(17)35304-1","article-title":"Serial prostate biopsies in men with persistently elevated serum prostate-specific antigen values","volume":"151","author":"Keetch","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0090-4295(99)80091-0","article-title":"Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy","volume":"45","author":"Partin","year":"1995","journal-title":"Urology"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB22","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.1999.17.5.1499","article-title":"Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer","volume":"17","author":"Kattan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0090-4295(00)00981-X_BIB23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00005392-200101000-00030","article-title":"Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy","volume":"165","author":"Blute","year":"2001","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950000981X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950000981X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T13:14:18Z","timestamp":1580217258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042950000981X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["S009042950000981X"],"URL":"https:\/\/doi.org\/10.1016\/s0090-4295(00)00981-x","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2001,4]]}}}